These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 38672414)

  • 21. [Advances of immunotherapy in small cell lung cancer].
    Liu J; Zhang S; Li H; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2014 Jun; 17(6):474-80. PubMed ID: 24949688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer.
    Obermayr E; Agreiter C; Schuster E; Fabikan H; Weinlinger C; Baluchova K; Hamilton G; Hochmair M; Zeillinger R
    Cells; 2019 Aug; 8(8):. PubMed ID: 31412616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
    Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
    Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring.
    Li W; Liu JB; Hou LK; Yu F; Zhang J; Wu W; Tang XM; Sun F; Lu HM; Deng J; Bai J; Li J; Wu CY; Lin QL; Lv ZW; Wang GR; Jiang GX; Ma YS; Fu D
    Mol Cancer; 2022 Jan; 21(1):25. PubMed ID: 35057806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Different Facets of Liquid Biopsy: A Kaleidoscopic View.
    Eslami-S Z; Cortés-Hernández LE; Cayrefourcq L; Alix-Panabières C
    Cold Spring Harb Perspect Med; 2020 Jun; 10(6):. PubMed ID: 31548226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies.
    Goswami M; Schlom J; Donahue RN
    Oncotarget; 2023 Aug; 14():758-774. PubMed ID: 38958745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.
    Hamilton G; Hochmair M; Rath B; Klameth L; Zeillinger R
    Cell Adh Migr; 2016 Jul; 10(4):360-7. PubMed ID: 26919626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunotherapy Advances in Small Cell Lung Cancer].
    Xu Y; Zhan P; Song Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):989-998. PubMed ID: 32752583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer.
    Yu L; Lai Q; Gou L; Feng J; Yang J
    J Drug Target; 2021 Jan; 29(1):1-11. PubMed ID: 32700566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation.
    Ren F; Fei Q; Qiu K; Zhang Y; Zhang H; Sun L
    J Exp Clin Cancer Res; 2024 Apr; 43(1):96. PubMed ID: 38561776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
    Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
    Su Z; Wang Z; Ni X; Duan J; Gao Y; Zhuo M; Li R; Zhao J; Ma Q; Bai H; Chen H; Wang S; Chen X; An T; Wang Y; Tian Y; Yu J; Wang D; Xie XS; Bai F; Wang J
    Clin Cancer Res; 2019 Aug; 25(16):5049-5060. PubMed ID: 31113842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.
    Eslami-S Z; Cortés-Hernández LE; Sinoquet L; Gauthier L; Vautrot V; Cayrefourcq L; Avoscan L; Jacot W; Pouderoux S; Viala M; Thomas QD; Lamy PJ; Quantin X; Gobbo J; Alix-Panabières C
    Br J Cancer; 2024 Jan; 130(1):63-72. PubMed ID: 37973956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis.
    Wu J; Hu S; Zhang L; Xin J; Sun C; Wang L; Ding K; Wang B
    Theranostics; 2020; 10(10):4544-4556. PubMed ID: 32292514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atomic force microscopy as a nanomechanical tool for cancer liquid biopsy.
    Li M
    Biochem Biophys Res Commun; 2024 Nov; 734():150637. PubMed ID: 39226737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum liquid biopsy for brain tumours: a scoping analysis of practicable approaches in low- and middle-income countries.
    Bajwa MH; Khan MA; Urooj F; Khalid MU; Enam SA; Aziz HF; Siddiqui K; Bari ME; Mughal N
    J Pak Med Assoc; 2024 Mar; 74(3 (Supple-3)):S30-S51. PubMed ID: 39262064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
    Tian Y; Zhai X; Han A; Zhu H; Yu J
    J Hematol Oncol; 2019 Jun; 12(1):67. PubMed ID: 31253167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.
    Jiang Y; Chen Y; Cheng Q; Lu W; Li Y; Zuo X; Wu Q; Wang X; Zhang F; Wang D; Wang Q; Lv T; Song Y; Zhan P
    Cancer Immunol Immunother; 2024 Oct; 73(12):241. PubMed ID: 39358575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.